Diabetic Nephropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Diabetic Nephropathy Therapeutics Market Forecast to Display Modest Growth until 2017,The report identifies the key trends shaping and driving the global Diabetic Nephropathy Therapeutics market. GlobalData estimates that the global diabetic nephropathy (DN) therapeutics market valued $1.65 billion in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 7.6% during 2005–2010. However, during 2010–2017, the market is expected to record a CAGR of 5.2%, to reach $2.35 billion by 2017. This lower CAGR is primarily attributed to the patent expiration of marketed drugs: the Cozaar patent expiration in November 2011, the Avapro patent expiration in September 2011 and the Diovan patent expiration in March 2012. Other significant factors contributing to the decreased CAGR include the asymptomatic nature of the disease, often diagnosed at later stage, the increased use of generic and offlabel drugs. In addition, although disease awareness is high, patient compliance with drugs and diet regimen is low. The current competitive landscape consists of branded, generic and off-label drugs. GlobalData expects Reata Pharmaceuticals, Inc., Glycadia Pharmaceuticals, Inc., Angelini Group, NephroGenex Inc., Eli Lilly, Abbott Laboratories, FibroGen, Inc and Torrent Pharmaceuticals Limited to be key companies in this market in the future. GlobalData holds profiles of all of the above companies as they possess important pipeline drugs in early and late stage development for DN therapeutics. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Diabetic-NephropathyTherapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017 The existing market landscape remains competitive because the treatment of DN relies on older, more established therapies such as angiotensin-converting enzyme (ACE) inhibitors, ARBs (angiotensin receptor blockers), and calcium channel blockers (CCBs), diuretics and beta blockers. The market scenario will change following the launch of new disease modifying therapies such as ACEs inhibitor, antioxidant inflammation modulator, connective tissue growth factor (CTGF) Inhibitor, monocyte chemoattractant proteins (MCP) inhibitor, selective glycation inhibitor, transforming growth factor beta regulator, selective Endothelin-A Receptor (ETAR) antagonist, urotensin II receptor antagonist, IL-12 inhibitors and STAT-4 activator, Nox4 inhibitor, G protein-coupled receptors (GPCRs) antagonist, and erythropoiesis stimulating agent. GlobalData’s analysis demonstrates that the DN therapeutics pipeline is moderately strong, with 18 firstin- class molecules in various phases of preclinical and clinical development. Currently, 8 molecules are present in Phase II and 4 molecules are in Phase I of clinical development. These first-in-class molecules are in the early stage of clinical development, so their impact on the future market will be in the latter stages. GlobalData, the industry analysis specialist, has released its new report, “Diabetic Nephropathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source
of information and analysis on the global Diabetic Nephropathy Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Nephropathy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Nephropathy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDataâ€™s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Diabetic-Nephropathy-Therapeutics-PipelineAssessment-and-Market-Forecasts-to-2017 Visit our report store: http://www.globaldata.com For more details contact: firstname.lastname@example.org North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782
Published on Jun 8, 2011
Diabetic Nephropathy Therapeutics Market Forecast to Display Modest Growth until 2017,The report identifies the key trends shaping and drivi...